Valuation: Rekvina Laboratories Limited

Market Cap 218M 2.28M 1.98M 1.85M 1.7M 3.2M 3.25M 21.77M 8.54M 108M 8.57M 8.38M 364M P/E 2024
-167x
P/E 2025 -19.6x
Enterprise Value 220M 2.31M 2M 1.87M 1.71M 3.23M 3.29M 21.99M 8.63M 110M 8.66M 8.47M 367M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -
07-13 Surbhit Mukesh Shah, the managing director of Rekvina Laboratories Limited, Amit Mukesh Shah, the director of Rekvina Laboratories Limited and Dhruvalkumar Patel completed the acquisition of an additional 23.22% stake in Rekvina Laboratories Limited for INR 14.41 million. CI
05-21 Rekvina Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
03-15 Rekvina Laboratories Limited entered into agreement to acquire Radiant Parenterals Limited from Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel, Krima Surbhit Shah and Ami Amit Shah for approximately INR 140 million. CI
03-15 Surbhit Mukesh Shah and Amit Mukesh Shah, the directors of Rekvina Laboratories Limited and Dhruvalkumar Patel proposed to acquire an additional 47.94% stake in Rekvina Laboratories Limited for INR 28.9 million. CI
03-10 Rekvina Laboratories Limited announced that it expects to receive INR 4.6 million in funding CI
02-06 Rekvina Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-29 Rekvina Laboratories Limited Announces the Resignation of Chetanbhai Jayantibhai Patel as Non- Executive Independent Director and from Membership in Various Committees, Effective from 29 January 2026 CI
01-09 Rekvina Laboratories Limited Announces Resignation of Dhruvalkumar Jayantilal Patel as Non-Executive Independent Director, Effective January 9, 2026 CI
11-14 Rekvina Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
20/09/25 Rekvina Laboratories Limited Announces Shifting of the Registered Office CI
13/08/25 Rekvina Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
04/08/25 Rekvina Laboratories Limited Approves Shifting of the Registered Office CI
30/05/25 Rekvina Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
1 day-0.99%
1 week-1.19%
1 month-26.47%
3 months-42.26%
6 months+71.82%
Current year+455.56%
1 week 25
Extreme 25
25.5
1 month 25
Extreme 25
36
Current year 6.75
Extreme 6.75
46.65
1 year 6.75
Extreme 6.75
46.65
3 years 6.75
Extreme 6.75
46.65
5 years 3.8
Extreme 3.8
46.65
10 years 3.6
Extreme 3.6
46.65
Manager TitleAgeSince
Chief Executive Officer 44 21/05/2024
Director of Finance/CFO 42 01/09/2024
Compliance Officer - 03/12/2024
Director TitleAgeSince
Director/Board Member 44 31/07/2000
Director/Board Member - 05/10/2025
Director/Board Member 24 21/05/2024

Financials

2024 2025
Net sales - -
Net income -164K -1.72K -1.49K -1.39K -1.28K -2.41K -2.45K -16.39K -6.43K -81.65K -6.45K -6.31K -274K -1.37M -14.36K -12.48K -11.62K -10.67K -20.15K -20.46K -137K -53.76K -683K -53.94K -52.75K -2.29M
Net Debt 798K 8.36K 7.27K 6.76K 6.21K 11.73K 11.91K 79.73K 31.29K 397K 31.39K 30.71K 1.33M 2.22M 23.23K 20.2K 18.8K 17.26K 32.6K 33.1K 222K 86.97K 1.1M 87.26K 85.34K 3.7M
Date Price Change Volume
31/07/26 ₹25.00 -0.99% 1,284
30/07/26 ₹25.25 -0.28% 1,579
29/07/26 ₹25.32 +0.08% 22
24/07/26 ₹25.30 -4.89% 3,938
  1. Stock Market
  2. Stocks
  3. VINRKLB Stock